Cellectis S.A.

ALCLS

FR0010425595

Biotechnology & Medical Research

Real-time Euronext Paris Other stock markets 10:34:05 2024-05-21 am EDT			5-day change	1st Jan Change
2.57 ^EUR	-3.38%		-5.34%	-7.02%

May. 17	European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Friday Trading	MT
May. 13	European Equities Traded in the US as American Depositary Receipts Kick Off Week Higher	MT

Cellectis S.A. Announces Resignation of Eric Dutang as Chief Financial Officer, Effective January 3, 2022

November 24, 2021 at 04:06 pm EST

Cellectis S.A. announced that Eric Dutang, Chief Financial Officer of the company, will leave his position with the Company, effective January 3, 2022, to pursue new opportunities.

Latest news about Cellectis S.A.

European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Friday Trading	May. 17	MT
European Equities Traded in the US as American Depositary Receipts Kick Off Week Higher	May. 13	MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading; End Week Up Nearly 3%	May. 10	MT
Bank Stocks Lead European Equities Traded in the US as American Depositary Receipts Higher Tuesday	May. 07	MT
European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading	May. 06	MT
Cellectis: alliance with AstraZeneca finalized	May. 06	CF
Cellectis Secures $140 Million Additional Equity Investment From AstraZeneca	May. 06	MT
AstraZeneca: equity investment in Cellectis	May. 06	CF
AstraZeneca completes collaboration and investment deal with Cellectis	May. 06	AN
AstraZeneca Secures 44% Stake in French Biotech Cellectis	May. 06	MT
Cellectis S.A. announced that it has received $140 million in funding from AstraZeneca PLC	May. 05	CI
Cellectis CFO Bing Wang Retires, Interim CFO Appointed	May. 03	MT
Cellectis Announces Chief Financial Officer Changes	May. 02	CI
European Equities Traded in the US as American Depositary Receipts Rise Modestly Higher in Thursday Trading	May. 02	MT
Cellectis S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 29	CI
Cellectis S.A. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Apr. 29	CI
European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading, End Week Up 3.4%	Apr. 26	MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Thursday Trading	Apr. 25	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading	Apr. 24	MT
Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs	Apr. 22	CI
European Equities Traded in the US as American Depositary Receipts Rebound in Monday Trading	Apr. 22	MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading But End Week Down	Apr. 19	MT
European Equities Traded in the US as American Depositary Receipts Lower in Tuesday Trading	Apr. 16	MT
European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading	Apr. 15	MT
European Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading	Apr. 11	MT

Cellectis S.A. is a clinical-stage biotechnology company using its pioneering TALEN® genome-editing technology to develop innovative therapies for the treatment of serious diseases. Cellectis S.A. is developing the first CAR-T cell-based allogeneic immunotherapy therapeutics, inventing the concept of off-the-shelf, ready-to-use engineered CAR-T cells for the treatment of cancer patients, and a platform for performing therapeutic genetic modifications in hematopoietic stem cells in a various diseases. Capitalizing on its 23 years of expertise in genome engineering, its TALEN® genome editing technology and its pioneering PulseAgile electroporation technology, Cellectis S.A. is developing innovative product candidates using the power of the immune system to treat diseases with unmet medical needs. As part of its commitment to the search for curative cancer therapies, Cellectis S.A. is developing UCART product candidates directed at the unmet medical needs of patients with certain types of cancer, including acute myeloid leukemia, B-cell acute lymphoblastic leukemia, and multiple myeloma. HEAL is a new platform focused on hematopoietic stem cells for the treatment of blood disorders, immune deficiencies, and lysosomal storage diseases.

Sector

Biotechnology & Medical Research

Calendar

2024-06-19 - Momentum in Cell and Gene Therapy Symposium

More about the company

Income Statement Evolution

More financial data

Ratings for Cellectis S.A.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
CELLECTIS S.A.	-7.02%	207M
MODERNA, INC.	+40.49%	54.04B
LONZA GROUP AG	+45.38%	41.96B
IQVIA HOLDINGS INC.	-1.38%	41.92B
CELLTRION, INC.	-7.20%	28.35B
ICON PUBLIC LIMITED COMPANY	+12.61%	26.35B
ALNYLAM PHARMACEUTICALS, INC.	-21.17%	19B
BIO-TECHNE CORPORATION	+7.15%	13B
MEDPACE HOLDINGS, INC.	+28.79%	12.28B
UNITED THERAPEUTICS CORPORATION	+26.06%	12.19B

Other Biotechnology & Medical Research

Cellectis S.A.

Equities

ALCLS

FR0010425595

Biotechnology & Medical Research

Cellectis S.A. Announces Resignation of Eric Dutang as Chief Financial Officer, Effective January 3, 2022

Latest news about Cellectis S.A.

Chart Cellectis S.A.

Company Profile

Income Statement Evolution

Ratings for Cellectis S.A.

Quarterly revenue - Rate of surprise

Sector Other Biotechnology & Medical Research